10-Q · May 14, 2026
Provectus Biopharmaceuticals, Inc. reported a net loss of $1,290,454 for Q1 2026, a 13.2% increase from $1,140,108 in Q1 2025, due to a total absence of grant revenue this quarter and slightly reduced operating…
Earnings analysis · 10-Q
PVCT earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not contain the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, liquidity balances, and free cash flow cannot be assessed. The…
Read full summary
The supplied 10-Q extract does not contain the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, liquidity balances, and free cash flow cannot be assessed. The filing does disclose $1,360,000 of quarterly 2025 Notes proceeds and $1,695,000 for the first six months of 2026, alongside conversions of notes and accrued directors’ fees into Series D-1 preferred stock. Management reported effective disclosure controls, with no material changes in internal control during the quarter, while adding a risk factor covering U.S. trade policy, tariffs, and geopolitical conflicts.
What stood out
-
$1.36M of Quarterly Note Financing
The company received $1,360,000 of 2025 Notes proceeds during the three months ended June 30, 2026, including $1,245,000 from non-related parties.
-
$1.70M of Year-to-Date Financing
During the six months ended June 30, 2026, the company received $1,695,000 of 2025 Notes proceeds, providing additional liquidity but increasing reliance on financing.
-
Convertible Notes Converted
The company issued 203,859 shares of Series D-1 Convertible Preferred Stock upon conversion of $540,000 of principal and $43,434 of accrued interest on convertible notes.
What to watch
-
Trade Policy and Geopolitical Exposure
The filing adds an updated risk concerning U.S. trade policies, tariffs, international agreements, and geopolitical conflicts. The company received $1,695,000 of 2025 Notes proceeds during the six months ended June 30, 2026, highlighting the potential sensitivity of its financing-dependent operations to capital-market volatility and supply-chain disruptions.
-
Concentrated Related-Party Financing
The company’s financing included $240,000 of 2025 Notes proceeds from an officer and director during the six months ended June 30, 2026, while $100,000 came from a shareholder beneficially owning more than 10% of voting securities. These related-party sources may indicate limited access to diversified external funding.
Management's outlook
The supplied filing extract does not include quantitative revenue or EPS guidance. Prior outlook information was reported separately in the June 30, 2026 8-K.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.